Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTV Artiva Biotherapeutics	$2.77 +2.2%	$2.32	$1.47 ▼ $17.31	$66.19M	N/A	119,744 shs	29,248 shs
HOTH Hoth Therapeutics	$1.29 +3.2%	$1.29	$0.65 ▼ $3.80	$16.57M	0.66	231,000 shs	162,695 shs
INMB INmune Bio	$2.35 -0.4%	$3.46	$1.89 ▼ $11.64	$62.74M	0.97	2.56 million shs	419,787 shs
RPTX Repare Therapeutics	$1.55 +1.0%	$1.49	$0.89 ▼ $4.07	$65.94M	0.93	90,381 shs	29,326 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTV Artiva Biotherapeutics	-2.87%	+1.50%	+6.27%	+36.87%	-73.14%
HOTH Hoth Therapeutics	-1.57%	-3.85%	-5.30%	+48.88%	+83.28%
INMB INmune Bio	-1.67%	-7.81%	-0.84%	-68.53%	-64.72%
RPTX Repare Therapeutics	+0.33%	-3.46%	+2.33%	+16.29%	-50.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARTV Artiva Biotherapeutics	2.7912 of 5 stars	3.5	0.0	1.5	2.5	1.3
HOTH Hoth Therapeutics	2.5591 of 5 stars	3.5	5.0	1.3	0.0	0.6
INMB INmune Bio	2.1877 of 5 stars	3.3	2.0	2.0	1.7	0.6
RPTX Repare Therapeutics	2.2542 of 5 stars	3.3	3.0	0.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARTV Artiva Biotherapeutics	3.00	Buy	$17.00	513.72% Upside
HOTH Hoth Therapeutics	3.00	Buy	$4.00	210.08% Upside
INMB INmune Bio	2.57	Moderate Buy	$18.40	682.98% Upside
RPTX Repare Therapeutics	2.50	Moderate Buy	$4.50	190.32% Upside

Current Analyst Ratings Breakdown

Latest HOTH, RPTX, INMB, and ARTV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/30/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/23/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/2/2025	INMB INmune Bio	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $8.00
7/1/2025	INMB INmune Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/1/2025	INMB INmune Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Outperform ➝ Sector Underperform
6/30/2025	INMB INmune Bio	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
6/26/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/12/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/11/2025	ARTV Artiva Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$12.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARTV Artiva Biotherapeutics	$250K	270.68	N/A	N/A	$6.10 per share	0.45
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	$0.73 per share	N/A
INMB INmune Bio	$10K	6,246.30	N/A	N/A	$1.09 per share	2.16
RPTX Repare Therapeutics	$53.48M	1.25	N/A	N/A	$2.57 per share	0.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARTV Artiva Biotherapeutics	-$65.37M	N/A	0.00	N/A	N/A	N/A	-42.60%	-37.76%	N/A
HOTH Hoth Therapeutics	-$8.19M	-$1.07	N/A	N/A	N/A	N/A	-114.32%	-105.92%	N/A
INMB INmune Bio	-$42.08M	-$2.48	N/A	N/A	N/A	N/A	-120.62%	-92.94%	10/30/2025 (Estimated)
RPTX Repare Therapeutics	-$84.69M	-$2.58	N/A	N/A	N/A	N/A	-78.25%	-66.85%	11/6/2025 (Estimated)

Latest HOTH, RPTX, INMB, and ARTV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	HOTH Hoth Therapeutics	-$0.27	-$0.17	+$0.10	-$0.17	N/A	N/A
8/8/2025	Q2 2025	RPTX Repare Therapeutics	-$0.56	-$0.39	+$0.17	-$0.39	$2.50 million	$0.25 million
8/7/2025	Q2 2025	INMB INmune Bio	-$0.37	-$0.34	+$0.03	-$1.05	$0.00 million	N/A
8/6/2025	Q2 2025	ARTV Artiva Biotherapeutics	-$0.84	-$0.87	-$0.03	-$0.87	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
RPTX Repare Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARTV Artiva Biotherapeutics	N/A	13.84	13.84
HOTH Hoth Therapeutics	N/A	27.54	27.54
INMB INmune Bio	N/A	4.20	4.20
RPTX Repare Therapeutics	N/A	6.30	6.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARTV Artiva Biotherapeutics	N/A
HOTH Hoth Therapeutics	7.08%
INMB INmune Bio	12.72%
RPTX Repare Therapeutics	85.09%

Insider Ownership

Company	Insider Ownership
ARTV Artiva Biotherapeutics	21.40%
HOTH Hoth Therapeutics	6.92%
INMB INmune Bio	35.70%
RPTX Repare Therapeutics	11.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARTV Artiva Biotherapeutics	81	24.43 million	19.20 million	N/A
HOTH Hoth Therapeutics	4	13.26 million	12.34 million	Not Optionable
INMB INmune Bio	10	26.58 million	17.09 million	Optionable
RPTX Repare Therapeutics	180	42.96 million	38.02 million	Optionable

HOTH, RPTX, INMB, and ARTV Headlines

Recent News About These Companies

Repare Therapeutics Announces Licensing Deal and Strategic Updates

August 12, 2025 | theglobeandmail.com

Repare Therapeutics (NASDAQ:RPTX) Posts Earnings Results

August 11, 2025 | marketbeat.com

Repare Therapeutics (NASDAQ:RPTX) Upgraded by Wall Street Zen to Hold Rating

August 11, 2025 | americanbankingnews.com

Repare Therapeutics (NASDAQ:RPTX) Stock Rating Upgraded by Wall Street Zen

August 10, 2025 | marketbeat.com

Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates

August 8, 2025 | zacks.com

Repare (RPTX) Q2 Loss Narrows 52%

August 8, 2025 | fool.com

Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

August 8, 2025 | financialpost.comF

Repare Therapeutics (RPTX) to Release Quarterly Earnings on Tuesday

July 30, 2025 | marketbeat.com

ARK Investment Management LLC Sells 875,514 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX)

July 27, 2025 | marketbeat.com

Repare Therapeutics (NASDAQ:RPTX) Trading 0.6% Higher - What's Next?

July 26, 2025 | marketbeat.com

Repare Therapeutics Jumps 15% After $10M Licensing Deal With Debiopharm

July 18, 2025 | uk.finance.yahoo.com

Repare Therapeutics Inc. (RPTX) - Yahoo Finance

July 17, 2025 | finance.yahoo.com

Repare inks licensing deal with Debiopharm for lunresertib

July 16, 2025 | thepharmaletter.comT

Repare finds suitor for paused PKMYT1 inhibitor in current partner Debiopharm

July 16, 2025 | fiercebiotech.comF

Repare Therapeutics Jumps After Hours On $267M Global Licensing Deal With Debiopharm; Retail Traders Rush In

July 16, 2025 | msn.com

Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib

July 15, 2025 | financialpost.comF

Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib

July 15, 2025 | financialpost.comF

Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib

July 15, 2025 | businesswire.com

Repare Therapeutics Inc (RPTX) - Investing.com

July 3, 2025 | investing.com

Repare Therapeutics Inc (RPTX) Stock Forums - Investing.com

June 30, 2025 | investing.com

Repare Therapeutics Out-Licenses Discovery Platforms to DCx Biotherapeutics in Strategic Deal

June 25, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOTH, RPTX, INMB, and ARTV Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

$2.77 +0.06 (+2.21%)

Closing price 04:00 PM Eastern

Extended Trading

$2.79 +0.02 (+0.72%)

As of 04:10 PM Eastern

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Hoth Therapeutics NASDAQ:HOTH

$1.29 +0.04 (+3.20%)

Closing price 04:00 PM Eastern

Extended Trading

$1.27 -0.02 (-1.55%)

As of 05:00 PM Eastern

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

INmune Bio NASDAQ:INMB

$2.35 -0.01 (-0.42%)

Closing price 04:00 PM Eastern

Extended Trading

$2.36 +0.01 (+0.60%)

As of 07:57 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Repare Therapeutics NASDAQ:RPTX

$1.55 +0.02 (+0.98%)

Closing price 04:00 PM Eastern

Extended Trading

$1.57 +0.02 (+1.55%)

As of 06:55 PM Eastern

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time